[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-stomach-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-stomach-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,63,90,129,157,194,221,242,259,278,382,409,436,457,485,511,529,548,567,589,609],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":41,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100644985","clonal-hematopoiesis-chemotherapy-and-radiation-effects-study-100644985",false,"NCT07675967","Clonal Hematopoiesis Chemotherapy and Radiation Effects Study","CH CARE","Inclusion Criteria:\n\n* Participants to be included in this study include the following:\n* Adults age \\>18 years\n* Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)\n* Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer).\n* Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past.\n\nExclusion Criteria:\n\n* Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure\n* Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)\n* Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation.","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.\n\nThe study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).\n\nUltimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Lung Cancer (Diagnosis)","Osteochondroma","Spitz Nevus","Solid Cancers","Breast Cancer","Gastric (Stomach) Cancer","Colorectal (Colon or Rectal) Cancer","Sarcoma","Ovarian Adenocarcinoma","Uterine Adenocarcinoma","Endometrial Adenocarcinoma","Esophageal Adenocarcinoma","Head and Neck Cancer","Therapy-Related Acute Myeloid Leukemia","Therapy-Related MDS","Clonal Hematopoiesis of Indeterminate Potential (CHIP)","Clonal Cytopenia of Undetermined Significance",[42,43,44,45,46,47,48,49],"Adult cancer survivors","Precursor Lesions","clonal hematopoiesis","chemotherapy","radiation","therapy-related myeloid neoplasms","CCUS","clonal hematopoiesis of indeterminate potential","RECRUITING","2026-06-29",{"date":53,"type":54},"2026-06-30","ACTUAL",{"date":56,"type":54},"2025-04-04",{"date":58,"type":20},"2035-03-31",{"name":60,"class":61},"Dana-Farber Cancer Institute","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100629952","phase-1-a-first-in-human-phase-iiia-study-to-evaluate-da-3501-in-patients-with-advanced-gastric-or-gastro-esophageal-junction-adenocarcinoma-and-pancreatic-ductal-adenocarcinoma-100629952","NCT07481357","A First-In-Human Phase I\u002FIIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","A First-In-Human Phase I\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n1. Patients aged ≥ 19 years\n2. Histologically or cytologically documented advanced CLDN18.2+ GC\u002FGEJ adenocarcinoma or advanced CLDN18.2+ PDAC\n3. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)\n4. Life expectancy ≥12 weeks as judged by the Investigator\n\nExclusion Criteria:\n\n1. Cardiac abnormalities\n2. Gastrointestinal abnormalities\n3. Active and clinically significant bacterial, fungal, or viral infection, including known hepatitis B virus (HBV), known hepatitis C virus (HCV), known human immunodeficiency virus (HIV).\n4. Active systemic infection requiring IV antibiotics therapy.","19 Years",{"count":72,"type":20},51,"INTERVENTIONAL",[75],"PHASE1","The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC\u002FGEJ and advanced CLDN18.2+ PDAC.\n\nParticipants will receive the assigned dose once every three weeks and, according to the study procedures, will undergo tumor assessments as well as safety assessments, PK evaluations, and ADA testing.",[29,78,79],"GastroEsophageal Cancer","Pancreatic Ductal Adenocarcinoma (mPDAC)","2026-05-18",{"date":82,"type":54},"2026-05-20",{"date":80,"type":54},{"date":85,"type":20},"2029-02",{"name":87,"class":88},"Dong-A ST Co., Ltd.","INDUSTRY",3,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":73,"phases":99,"briefSummary":101,"conditions":102,"keywords":115,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100633678","phase-1-phase-12-study-of-bhb810-in-advanced-gastric-and-gej-adenocarcinoma-100633678","NCT07529808","Phase 1\u002F2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","Phase 1\u002F2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.\n* Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.\n\n  * Participants in Phase 1 Backfill Cohorts \\& Phase 2 must be CDH17-positive by central testing.\n  * Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.\n* At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)\n* Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.\n* Adequate organ and marrow function as defined in the protocol\n\nExclusion Criteria:\n\n* Prior cancer treatment as follows, relative to the first planned dose of trial intervention:\n\n  * Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)\n  * Monoclonal antibody-based therapy (including ADCs) within 4 weeks\n  * Immune checkpoint inhibitors within 4 weeks\n  * Wide-field radiation therapy (\\>30% marrow-bearing bones) within 4 weeks or \\\u003C 2 weeks of focal palliative radiation to nontarget lesions\n* Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)\n* Known hypersensitivity or allergic reaction to BHB810 or it's excipients\n* Left ventricular ejection fraction \\\u003C50% or history of congestive heart failure Class III\u002FIV\n* QTc interval \\> 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT\u002FQTc\n* Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant\n* Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.\n* Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention\n* Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.",{"count":98,"type":20},164,[75,100],"PHASE2","This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.",[103,104,29,105,106,107,108,109,110,111,30,112,113,114],"Gastric Cancer","Gastric Adenocarcinoma","Gastroesophageal Adenocarcinoma","Gastroesophageal Cancer (GC)","Gastroesophageal Junction (GEJ) Adenocarcinoma","Gastroesophageal Junction (GEJ) Cancer","Gastrointestinal Cancer Metastatic","Gastrointestinal Adenocarcinoma","Gastrointestinal Cancers","Pancreatic Cancer","CDH17-positive Advanced Solid Tumors","Advanced Gastric Cancer",[116,117,118],"Antibody Drug Conjugate (ADC)","Monomethyl Auristatin E (MMAE)","CDH17 protein","NOT_YET_RECRUITING","2026-05-05",{"date":122,"type":54},"2026-05-08",{"date":124,"type":20},"2026-06",{"date":126,"type":20},"2028-12",{"name":128,"class":88},"BigHat Biosciences, Inc.",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":73,"phases":139,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100592962","phase-2-timing-of-minimally-invasive-local-treatment-after-first-line-systemic-therapy-in-oligometastatic-esophageal-or-gastric-adenocarcinoma-100592962","NCT07000253","Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma","Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma: A Randomized Prospective Clinical Study (OMEC-5)","OMEC-5","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to provide written informed consent\n* Histologically confirmed esophageal, gastric or gastroesophageal junction tumor with oligometastatic (M1) disease defined according to the OMEC consensus statement:\n\n  * One organ with ≤3 metastases or 1 involved extra-regional lymph node station (based on the TNM 8 classification)\n  * ≤3 unilobar liver metastases or ≤2 bilobar liver metastases\n  * ≤ 3 unilateral lung metastases\n  * Unilateral adrenal gland involvement\n  * Metastasis confined to 1 bone structure or 1 soft tissue compartment\n* Synchronous oligometastatic disease with a resectable primary tumor or metachronous oligometastatic disease (in the event of a locoregional recurrence this should be resectable)\n* Metastases should be deemed amenable by the international multidisciplinary expert team for radical local treatment\n* WHO performance status 0-2\n* Indication for checkpoint inhibition and\u002For targeted therapy\n\n  * PD-L1 with a CPS of 1 or higher as per local clinical practice for immunotherapy use\n  * HER2 overexpression as per local clinical practice for trastuzumab use\n  * Claudin 18.2 overexpression as per local clinical practice for zolbetuximab use.\n  * Any other biomarker that allows targeted therapy in first line approved by EMA\n* No prior systemic therapy for metastatic disease\n* CT-scan ≤8 weeks prior to inclusion\n* Ability to undergo local treatment and start systemic treatment beyond 18 weeks of total systemic treatment.\n\nExclusion Criteria:\n\n* Squamous cell carcinoma\n* Brain metastases\n* Peritoneal or pleural carcinomatosis\n* Patients with MSI dMMR\n* Uncontrolled immunodeficiency (e.g. AIDS)\n* Peripheral neuropathy \\>CTCAE grade 1, precluding start of full dose oxaliplatin treatment\n* Both organ metastasis and extra-regional lymph node metastasis\n* Conditions precluding local treatment or systemic therapy for oligometastatic disease:\n\n  * Serious medical comorbidities precluding local treatment (e.g., interstitial lung disease in patients with pulmonary metastasis)\n  * Clinical or radiological evidence of spinal cord compression or epidural tumor within 2 mm of the spinal cord\n  * Simultaneous other malignancy or previous other malignancy with a disease-free period of \\\u003C5 years, except adequately treated non-melanoma skin cancer or in-situ cancers\n  * Uncontrolled (bacterial) infections\n  * Significant concomitant diseases preventing the safe administration of study drugs or likely to interfere with study assessments\n  * Uncontrolled angina pectoris, cardiac failure or clinically significant arrhythmias\n  * Continuous use of immunosuppressive agents equivalent to \\>10 mg daily prednisone\n  * Concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine\n  * Pregnancy or breast feeding\n  * Patients (M\u002FF) with reproductive potential not implementing adequate contraceptive measures",{"count":138,"type":20},290,[100,140],"PHASE3","Purpose of the Study:\n\nThis clinical study investigates whether a shorter or longer duration of systemic therapy before local treatment (surgery or radiation) results in better disease control in patients with esophageal or gastric cancer with a limited number of metastases, also known as oligometastases.\n\nBackground:\n\nIn about 25% of patients with advanced esophageal or gastric cancer, the disease spreads to only a few sites (oligometastatic disease). Prior studies suggest that local treatment after systemic therapy may extend survival in this subgroup. However, it is unclear how long systemic therapy should last before initiating local treatment. The OMEC-5 study aims to clarify this and identify potential biomarkers for treatment response.\n\nStudy Design:\n\nInitiated by Amsterdam UMC and UMCU and conducted in multiple hospitals across Europe.\n\nTotal of 414 patients to be enrolled.\n\nDuration: \\~53 months (35 months enrollment + 18 months follow-up).\n\nApproved by the medical ethics committee at Amsterdam UMC.\n\nProcedure:\n\nEligibility screening: Includes physical exam, blood tests (incl. circulating tumor cells), medical history review, and confirmation of oligometastases by an expert panel.\n\nInitial treatment: All participants receive 4 months of standard systemic therapy (chemotherapy + immunotherapy and\u002For targeted therapy depending on tumor markers like HER2 or Claudin 18.2).\n\nResponse assessment (Review 1): Imaging and\u002For laparoscopic examination.\n\nIf oligometastases persist and tumors have not progressed, participants are randomized into two groups:\n\nGroup A (longer systemic therapy): 4 more months of systemic therapy, then local treatment if disease is stable, followed by 4 months of immunotherapy ± targeted therapy.\n\nGroup B (shorter systemic therapy): Immediate local treatment followed by 4 months of systemic therapy, then reassessment and potentially 4 months of immunotherapy ± targeted therapy.\n\nFollow-up: Regular scans and quality-of-life questionnaires (5 times), and periodic blood sampling (4 times).\n\nTreatments Involved:\n\nChemotherapy: CapOx or FOLFOX\n\nImmunotherapy: nivolumab or pembrolizumab\n\nTargeted therapy: trastuzumab (HER2-positive) or zolbetuximab (Claudin 18.2-positive)\n\nPotential Benefits and Risks:\n\nPatients may benefit from better disease control and a personalized treatment strategy.\n\nKnown side effects relate to the standard treatments used (chemo, immuno, targeted therapies), and no extra medical risk is expected beyond routine care.\n\nPossible inconveniences include blood draws, scans, minor surgery (laparoscopy), and time investment.\n\nData and Sample Handling:\n\nPersonal data and tumor\u002Fblood samples are coded and securely stored.\n\nData may be used for future cancer research if the patient consents.\n\nParticipants can withdraw at any time.\n\nConfidentiality and Privacy:\n\nPatient data are kept confidential, and participants have rights to access or delete their data. Privacy measures comply with GDPR and Dutch law.\n\nCompensation and Insurance:\n\nParticipation is voluntary, with no financial compensation. Standard treatment costs are covered by healthcare insurance. No extra insurance is required, as the treatment aligns with standard care practices.",[143,29,104,144,145,146],"Esophageal Cancer","Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","Esophageal Carcinoma","Gastric (Cardia, Body) Cancer","2026-05-03",{"date":149,"type":54},"2026-05-07",{"date":151,"type":54},"2026-04-29",{"date":153,"type":20},"2034-01",{"name":155,"class":61},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",2,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100629933","study-of-the-epidemiological-clinical-diagnostic-and-therapeutic-characteristics-of-gastric-cancers-in-algeria-100629933","NCT07481110","Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria","ECLIPSE-CG","Inclusion Criteria:\n\n* Patients aged 19 years and older\n* Histologically confirmed diagnosis of gastric cancer\n* Patients followed in the participating oncology departments\n* Informed consent obtained\n\nNon Inclusion Criteria:\n\n* Histological types other than carcinoma (e.g., GIST, lymphoma, sarcoma, etc.).\n* Secondary gastric tumors\n* Participation in an interventional study",{"count":165,"type":20},1000,"The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer.\n\nIt also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.",[103,29,168],"Gastric Cancer (Diagnosis)",[103,170,171,172,173,174,175,176,177,178,179,180,181,182,183],"Gastric cancer in Algerian patients","Observational study","Patient outcomes","Oncology","Retrospective data","Treatment strategies","Diagnostic approaches","Clinical characteristics","Epidemiological data","Demographic data","Cross-sectional study","Real-world data","Algeria","Algerian Study","2026-03-25",{"date":186,"type":54},"2026-03-27",{"date":188,"type":54},"2025-08-05",{"date":190,"type":20},"2026-08-05",{"name":192,"class":61},"Société Algérienne de Formation et Recherche en Oncologie",15,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":73,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":62},"100627316","phase-2-riluzole-for-preventing-cognitive-dysfunction-in-ca-pts-receiving-chemo-refocus-pilot-trial-100627316","NCT07447050","Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial","RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)","Inclusion Criteria:\n\n* Female and male patients diagnosed with cancer and planned to receive an anthracycline- or platinum- containing chemotherapy regimen.\n* ≥18 years of age.\n* Life expectancy \\> 6 months\n* Able to provide informed consent.\n* Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes. Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n* Presence of primary brain tumors or brain metastases.\n* Receive a primary chemotherapy regimen that does not include anthracycline- or platinum- containing chemotherapy.\n* Unwilling to undergo neuropsychological assessments necessary for the study.\n* Patients who are breastfeeding, pregnant or are planning to get pregnant during the study period. POCBP must have a negative pregnancy test at screening if there is suspicion of pregnancy. Patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n* History of or suspected hypersensitivity to riluzole or to any of its excipients.\n* Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n* Hepatic impairment as indicated by: AST and\u002For ALT ≥ 3 X upper limit normal (ULN).\n* Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.",{"count":202,"type":20},24,[100],"This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.",[28,31,29,206,36,207,208,209,210,211],"Lung Cancer","Colorectal Cancer","Ovarian Cancer","Liver Cancer","Genitourinary Cancer","Gynecologic Cancer","2026-02-25",{"date":214,"type":54},"2026-03-03",{"date":216,"type":54},"2025-12-23",{"date":218,"type":20},"2028-12-31",{"name":220,"class":61},"University of California, Irvine",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":16,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":62},"100588623","prospective-gastric-cancer-screening-with-fecal-multi-target-dna-analysis-100588623","NCT06943807","Prospective Gastric Cancer Screening With Fecal Multi-target DNA Analysis","A Prospective Study of Gastric Cancer Screening Based on Fecal Multi-Target DNA Analysis Combined With a Risk Questionnaire","Inclusion Criteria:\n\n1. Age ≥40 years, male or female.\n2. No contraindications to endoscopy and able to cooperate with endoscopy.\n3. Patients must be able to fully understand the informed consent form and be able to sign the informed consent form in person.\n\nExclusion Criteria:\n\n1. A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.\n2. Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.\n3. Severe mental illness or incapacity to participate in the study due to lack of civil behavior.\n4. Pregnant or breastfeeding women.\n5. Other conditions that the investigator deems inappropriate for participation in the study.",true,"40 Years",{"count":231,"type":20},15000,"This is a prospective study designed to evaluate the efficacy of a multi-target fecal DNA test for the early detection of gastric cancer. The test combines Helicobacter pylori gene detection with analysis of fecal methylated DNA markers. The primary objective is to assess whether each method, individually or in combination, can facilitate earlier diagnosis of gastric cancer. All participants will undergo the multi-target fecal DNA test and complete the gastric cancer risk questionnaire.",[29],"2026-02-23",{"date":212,"type":54},{"date":237,"type":54},"2025-07-01",{"date":239,"type":20},"2027-12-30",{"name":241,"class":61},"Fudan University",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":228,"sex":16,"minAge":229,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":256,"leadSponsor":258,"locationsCount":62},"100584977","an-observational-study-for-gastric-cancer-in-carriers-of-high-risk-helicobacter-pylori-100584977","NCT06896370","An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori","Risk of Gastric Cancer in High-risk Carriers of Helicobacter Pylori: an Observational Cohort Study","Inclusion Criteria :\n\n1. Age ≥ 40 years, gender is not limited.\n2. Able and willing to provide informed consent and willing to undergo baseline and follow-up examinations.\n\nExclusion Criteria:\n\n1. A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.\n2. Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.\n3. Severe mental illness or incapacity to participate in the study due to lack of civil behavior.\n4. Pregnant or breastfeeding women.\n5. Other conditions that the investigator deems inappropriate for participation in the study.",{"count":250,"type":20},3000,"This study is intended to be a prospective observational cohort study. The incidence of gastric cancer and progression of gastric precancerous lesions will be compared between groups through prospective follow-up of a population with baseline negative gastric endoscopy, harboring high-risk Hp SNP subtypes and non-high-risk subtypes.",[29,253],"Helicobacter Infection",{"date":212,"type":54},{"date":237,"type":54},{"date":257,"type":20},"2035-12-31",{"name":241,"class":61},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":228,"sex":16,"minAge":229,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":73,"phases":268,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":62},"100588622","eradication-of-helicobacter-pylori-subtypes-at-high-gastric-cancer-risk-a-cluster-randomized-controlled-trial-100588622","NCT06943794","Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial","Gastric Cancer Prevention Strategies Based on Eradication of Helicobacter Pylori Subtypes at High Risk for Gastric Cancer: a Practical Cluster-randomized Controlled Trial","Inclusion Criteria :\n\n1. Age ≥ 40 years, gender is not limited.\n2. Voluntary participation with signed informed consent.\n3. No H. pylori eradication treatment received within the past 1 month.\n4. Able to complete stool sample collection and related examinations as per study requirements.\n5. Detected as high-risk by Hp subtype test.\n\nExclusion Criteria:\n\n1. A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.\n2. Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.\n3. Severe mental illness or incapacity to participate in the study due to lack of civil behavior.\n4. Pregnant or breastfeeding women.\n5. Other conditions that the investigator deems inappropriate for participation in the study.",{"count":267,"type":20},4824,[269],"NA","This study is a prospective, multicenter cluster randomized controlled trial. Additional fecal screening for high-risk SNP subtypes, in conjunction with routine Hp testing, may improve the identification of individuals at high risk for gastric cancer. Moreover, the implementation of eradication interventions in high-risk groups has the potential to significantly reduce the incidence and progression of gastric cancer.",[29],{"date":212,"type":54},{"date":274,"type":20},"2026-03-30",{"date":276,"type":20},"2030-12-30",{"name":241,"class":61},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":73,"phases":288,"briefSummary":289,"conditions":290,"keywords":367,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":62},"100432171","virtual-reality-for-gi-cancer-pain-to-improve-patient-reported-outcomes-100432171","NCT04907643","Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","Inclusion Criteria:\n\n* Have a primary malignancy of the biliary tract, colon, liver, pancreas, peritoneum, rectum, small intestine, or stomach, with no plan for resection during the study period\n* Tumor types including, but not limited to, adenocarcinoma, squamous cell carcinoma, neuroendocrine tumors, and tumors of mesenchymal origin will be eligible\n* Have clinically significant visceral pain, measured using the standardized NIH PROMIS GI Pain Scale defined as scoring at least 5 points above the nationally normed score\n* Ability to read and write in English\n\nExclusion Criteria:\n\n* Have a condition that interferes with VR usage, including but not limited to seizures, facial injury precluding safe placement of headset, and visual impairments\n* Have cognitive impairment that affects protocol participation. This will be done with a three part cognitive assessment during the initial phone call to assess eligibility followed by consent discussion if eligible.\n* Have brain metastases\n* Have a prognosis of \\\u003C3 months from the time of enrollment per treating oncologist","99 Years",{"count":287,"type":20},360,[269],"Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Users of VR wear a pair of goggles with a close-proximity screen in front of the eyes that creates a sensation of being transported into lifelike, three-dimensional worlds. To date, VR has been limited to short-term clinical trials for cancer pain. Moreover, limited research exists on theory-based VR modalities beyond mere distraction, such as VR that employs acceptance and commitment therapy (ACT) with components of biofeedback and mindfulness. To bridge these gaps, this study seeks to: (1) assess the impact of immersive VR on patient-reported outcomes (PROs), including pain, activity metrics, and opioid use among patients with visceral pain from a digestive tract malignancy; (2) assess differences in PROs, activity metrics, and opioid use between skills-based VR therapy vs. distraction VR therapy; and (3) determine patient-level predictors of VR treatment response in visceral cancer pain.\n\nTo address these aims, the study will measure PROs and opioid use in 360 patients randomized among 3 groups and follow them for 60 days after enrollment: (1) an enhanced VR group receiving skills-based VR; (2) a distraction-based VR group receiving patient-selected VR videos; and (3) a VR sham control group using a VR headset with 2-D content. The results will inform best practices for the implementation of VR for visceral cancer pain management and guide selection of patient-tailored experiences.",[291,292,293,294,295,296,209,297,298,299,300,301,109,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,29,358,359,360,361,362,363,364,365,366],"Cancer Pain","Visceral Pain","Gastrointestinal Neoplasms","Cancer of Gastrointestinal Tract","Small Intestine Cancer","Pancreas Cancer","Colon Cancer","Biliary Tract Cancer","Stomach Cancer","Rectum Cancer","Peritoneal Cancer","Gastrointestinal Cancers - Anus","Gastrointestinal Cancers - Stomach","Gastrointestinal Cancers - Colorectal","Gastrointestinal Cancers - Small Intestine","Small Intestine Cancer Stage III","Small Intestine Cancer Stage IV","Small Intestine Cancer, Recurrent","Pancreas Cancer, Stage III","Pancreas Cancer, Stage IV","Pancreas Cancer, Metastatic","Pancreas Cancer, Recurrent","Liver Cancer Stage IIIa","Liver Cancer Stage IIIb","Liver Cancer Stage IIIc","Liver Cancer Stage IV","Colon Cancer Stage III","Colon Cancer Stage IV","Stomach Cancer Stage III","Stomach Cancer Stage IV","Stomach Cancer Recurrent","Rectum Cancer, Recurrent","Gastrointestinal Cancers - Liver","Anal Cancer","Anal Cancer Stage III","Anal Cancer Stage IV","Anal Cancer Recurrent","Anal Cancer Metastatic","Anal Cancer, Stage IIIA","Anal Cancer, Stage IIIB","Appendix Cancer","Ampullary Cancer","Bile Duct Cancer","Bile Duct Cancer Stage III","Bile Duct Cancer Stage IV","Bile Duct Cancer Stage IVA","Bile Duct Cancer Stage IVB","Bile Duct Cancer Recurrent","Carcinoid Tumor","Carcinoid Tumor of Pancreas","Carcinoid Tumor of Large Intestine","Carcinoid Tumor of GI System","Carcinoid Tumor of Colon","Carcinoid Tumor of Liver","Carcinoid Tumor of Cecum","Carcinoid Tumor of Ileum","Carcinoid Tumor of Rectum","Carcinoid Tumor of the Small Bowel","Carcinoid Tumor of the Stomach","Large Intestine Cancer","Esophagus Cancer","Esophagus Cancer, Stage III","Esophagus Cancer, Stage IV","Esophagus Cancer, Recurrent","Gallbladder Cancer","Gallbladder Cancer Stage III","Gallbladder Cancer Stage IV","Neuroendocrine Tumor","Peritoneum Cancer","Rectal Cancer","Esophagus Cancer, Stage I","Esophagus Cancer, Stage II","Gallbladder Cancer Stage I","Gallbladder Cancer Stage II","Bile Duct Cancer Stage I","Bile Duct Cancer Stage II",[368,369,370,371,372],"Virtual Reality","VR","support","GI cancer","cancer pain","2026-02-18",{"date":375,"type":54},"2026-02-20",{"date":377,"type":54},"2021-10-05",{"date":379,"type":20},"2027-03-16",{"name":381,"class":61},"Cedars-Sinai Medical Center",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":73,"phases":391,"briefSummary":392,"conditions":393,"keywords":397,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":89},"100621518","phase-1-an-phase-ibii-clinical-trial-of-tcc1727-combination-therapy-in-advanced-solid-tumors-100621518","NCT07371663","An Phase Ib\u002FII Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","An Open-Label, Multicenter Phase Ib\u002FII Clinical Trial of TCC1727 in Combination With Benmelstobart\u002FOlaparib\u002FTopotecan for Advanced Solid Tumors","Inclusion Criteria:\n\n* -Voluntarily participate in this study and sign the informed consent form.\n* At the time of signing the informed consent, subjects must be ≥18 years of age (inclusive).\n* Subjects must have histologically or cytologically confirmed advanced or metastatic solid tumors and have experienced disease progression following prior standard anti-tumor therapy; or subjects must have no available standard therapy, be intolerant to or refuse standard therapy, or meet the specific requirements for the corresponding phase and group as follows:\n\n  * Phase Ib :Subjects with advanced, recurrent, or refractory solid tumors, which may include (but are not limited to) the specific tumor types in Phase II.\n  * Phase II Study:Based on different combination therapy groups, subjects with the following specific tumor types (different population cohorts):\n\nTCC1727 combined with Benmelstobart Group:\n\nThe study will enroll subjects with advanced solid tumors lacking standard therapies, including but not limited to non-small cell lung cancer (NSCLC), endometrial cancer, and other advanced solid tumors (e.g., colorectal cancer, urothelial carcinoma, gastric cancer, and gastroesophageal junction cancer):\n\nCohort 1 (NSCLC):Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC who are eligible for second- or third-line therapy. Patients must have received prior therapy with an anti-PD-(L)1-containing regimen (either as monotherapy or in combination) and a platinum-based doublet regimen for locally advanced or metastatic NSCLC.\n\nSubgroup 1: ATM mutation. Subgroup 2: ATM wild-type, with or without other DDR functional defects.\n\nCohort 2 (Endometrial Cancer):Patients with histopathologically confirmed recurrent or metastatic advanced endometrial cancer who have received at least one prior platinum-based chemotherapy and immune checkpoint inhibitor (PD-1 or PD-L1) therapy (sequential or concurrent therapy allowed; sequential therapy refers to platinum-based chemotherapy followed by immune checkpoint inhibitor maintenance therapy).\n\nSubgroup 1: DDR functional defect, ATM wild-type or mutated. Subgroup 2: DDR functional normal.\n\nCohort 3 (Other Advanced Solid Tumors):Patients with histologically or cytologically confirmed advanced malignant solid tumors who have failed standard therapy, are intolerant to standard therapy, have no standard therapy available, or for whom standard therapy is currently unsuitable.\n\nSubgroup 1: DDR functional defect, ATM wild-type or mutated. Subgroup 2: DDR functional normal.\n\nTCC1727 combined with Olaparib Tablets Group:\n\nThe study will enroll subjects with histopathologically confirmed recurrent ovarian cancer:\n\nCohort 4 (Ovarian Cancer):Subjects with histopathologically confirmed recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer:\n\nSubgroup 1: Subjects who have experienced disease progression after prior Olaparib Tablets therapy (maintenance or subsequent therapy). Subjects must not have received further treatment after progression on Olaparib Tablets.\n\nSubgroup 2: Subjects who have not received Olaparib Tablets and have primary platinum-resistant\u002Frefractory disease (recurrence within 6 months of last platinum-based therapy). Subjects must have received ≤3 prior lines of therapy since developing platinum resistance.\n\nTCC1727 combined with Topotecan Hydrochloride for Injection Group:\n\nThe study will enroll subjects with histopathologically or cytologically confirmed small cell lung cancer (SCLC):\n\nCohort 5 (SCLC):Subjects who have progressed after platinum-based chemotherapy combined with PD-(L)1 therapy, or subjects with extensive-stage SCLC who have relapsed or progressed within ≤6 months after first-line therapy.\n\n* At least one measurable lesion (per RECIST v1.1; lesions previously treated with local therapy may be considered target lesions if they show clear progression per RECIST v1.1).\n* Subjects must provide sufficient tumor tissue samples, including but not limited to fresh specimens (preferred) or formalin-fixed, paraffin-embedded (FFPE) tumor tissue obtained within approximately 24 months prior to randomization, unstained FFPE slides, or core needle biopsy tissue for biomarker testing.\n* ECOG performance status score of 0-1 within 7 days prior to the first dose of study drug.\n* Expected survival ≥12 weeks.\n* Ability to swallow tablets whole and maintain this method of administration.\n* Organ function within the following ranges within 7 days prior to the first dose of study drug (no blood component or growth factor therapy within 14 days prior to the first dose):\n\n  1. Absolute neutrophil count (ANC) ≥1.5 × 10⁹\u002FL;\n  2. White blood cell count (WBC) ≥3.0 × 10⁹\u002FL;\n  3. Platelet count ≥100 × 10⁹\u002FL;\n  4. Hemoglobin (Hb) ≥90 g\u002FL;\n  5. Serum albumin ≥30 g\u002FL;\n  6. Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for hepatocellular carcinoma or subjects with liver metastases);\n  7. ALT and AST ≤3 × ULN (≤5.0 × ULN for hepatocellular carcinoma or subjects with liver metastases);\n  8. Alkaline phosphatase (ALP) ≤2.5 × ULN (≤5 × ULN if bone metastases are present);\n  9. Serum creatinine ≤1.5 × ULN or creatinine clearance (CrCL) ≥60 mL\u002Fmin (Cockcroft-Gault formula);\n  10. APTT ≤1.5 × ULN and INR or PT ≤1.5 × ULN (for subjects not receiving anticoagulation therapy);\n  11. QTc \\\u003C450 ms (male) or \\\u003C470 ms (female), LVEF ≥50%.\n* For non-sterilized or fertile female subjects, medically approved contraception (e.g., intrauterine device, oral contraceptives, or condoms) must be used during the study and for 6 months after the last dose. Non-sterilized female subjects must have a negative serum HCG test within 72 hours before the first dose and must not be breastfeeding. Male subjects with fertile partners must use effective contraception during the study and for 3 months after the last dose.\n\nExclusion Criteria:\n\n* Known primary central nervous system (CNS) tumors (including meningeal tumors); symptomatic brain metastases, spinal cord compression, carcinomatous meningitis, or uncontrolled CNS metastases. Exceptions: Subjects with completely resected and\u002For irradiated CNS metastases that are stable or improved for ≥4 weeks before screening (no evidence of brain edema and no need for corticosteroids or anticonvulsants). Asymptomatic brain metastases \\\u003C1 cm in diameter without surrounding edema are also allowed.\n* Major surgery, radiotherapy, chemotherapy, or other investigational anti-tumor therapy completed \\\u003C4 weeks before the first dose (exceptions: small-molecule anti-tumor therapy completed \\>5 half-lives or \\>10 days before the first dose, whichever is longer; palliative radiotherapy completed \\>2 weeks before the first dose).\n* Use of strong CYP3A4 inhibitors or inducers within 14 days before the first dose (e.g., rifampin, rifapentine, St. John's wort, carbamazepine, phenytoin, barbiturates, ketoconazole, itraconazole, clarithromycin, voriconazole, atazanavir, ritonavir, saquinavir, grapefruit juice).\n* Any unresolved ≥Grade 2 toxicity (per CTCAE v5.0) from prior anti-tumor therapy (except alopecia, pigmentation, or laboratory abnormalities meeting inclusion criteria).\n* Inability to swallow tablets, gastrointestinal dysfunction, or any condition that may affect drug absorption (per investigator's judgment).\n* Uncontrolled severe diseases, including:\n\n  1. Poorly controlled hypertension (systolic BP ≥150 mmHg or diastolic BP ≥100 mmHg);\n  2. Clinically significant cardiovascular disease within 6 months before the first dose (e.g., myocardial infarction, severe\u002Funstable angina, stroke, ≥Grade 2 congestive heart failure \\[NYHA classification\\]);\n  3. Arrhythmia (≥Grade 2 per CTCAE v5.0, including QTcF ≥450 ms \\[male\\] or ≥470 ms \\[female\\]);\n  4. Unexplained fever ≥38.5°C within 14 days before the first dose or active infection requiring systemic therapy;\n  5. Active viral hepatitis (HBV DNA ≥500 IU\u002FmL for HBsAg-positive and\u002For anti-HBc-positive subjects; HCV RNA-positive for anti-HCV-positive subjects; antiviral therapy required for eligible HBV\u002FHCV-positive subjects);\n  6. Active syphilis;\n  7. Active tuberculosis;\n  8. Immunodeficiency (e.g., HIV-positive, congenital\u002Facquired immunodeficiency, organ transplant history);\n  9. Poorly controlled diabetes (fasting blood glucose \\>10 mmol\u002FL).\n* Uncontrolled pleural effusion, pericardial effusion, ascites, or recurrent ascites requiring drainage within 28 days before the first dose.\n* Significant bleeding symptoms or tendency within 3 months before the first dose.\n* Chronic systemic corticosteroid therapy (\\>10 mg prednisone equivalent daily) or immunosuppressive therapy within 14 days before the first dose.\n* Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., immunomodulators, corticosteroids, immunosuppressants). Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement for adrenal\u002Fpituitary insufficiency) is allowed. (Applies only to Ib Phase and Phase II TCC1727 + Benmelstobart groups.)\n* History of severe allergic reactions to study drugs or their excipients.\n* Other malignancies within 3 years before screening (except cured basal cell carcinoma, cervical carcinoma in situ, or thyroid papillary carcinoma).\n* Prior ≥Grade 3 immune-mediated adverse events (imAEs) or permanent discontinuation due to imAEs during anti-PD-(L)1 therapy.\n* Prior treatment with TCC1727, other ATR inhibitors, or cell cycle checkpoint inhibitors (e.g., ATM inhibitors, WEE1 inhibitors, CHK1\u002FCHK2 inhibitors).\n* Other severe physical\u002Fmental illnesses or factors that may increase study risk or interfere with results, or any condition deemed unsuitable by the investigator.\n\nAdditional exclusions:\n\n* Phase II Cohort 1 (NSCLC):Exclude subjects with known EGFR, ALK, ROS1, BRAF, MET, RET, or RAS mutations; exclude mixed NSCLC\u002FSCLC histology.\n* Phase II Cohort 2 (Endometrial Cancer):Exclude uterine carcinosarcoma, endometrial leiomyosarcoma, or endometrial stromal sarcoma.\n* Phase II Cohort 3 (Other Solid Tumors):Exclude KRAS\u002FNRAS\u002FBRAF mutations or MSI-H status.\n* Phase II Cohort 4 (Ovarian Cancer) \\& Ib Phase TCC1727 + Olaparib Tablets: Exclude prior myelodysplastic syndrome or acute myeloid leukemia.",{"count":390,"type":20},266,[75,100],"This is a Phase Ib\u002FII clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart \u002Folaparib \u002Ftopotecanfor patients with advanced solid tumors.\n\nThe Phase II expansion study will assess the efficacy and safety of TCC1727 combined with benmelstobart \u002Folaparib\u002Ftopotecanin selected advanced solid tumor indications.\n\nThe study pre-specifies three treatment combinations, with Combination 1 (TCC1727 + benmelstobart) being prioritized for initial evaluation. The decision to proceed with Combination 2 and Combination 3will be based on clinical data from Combination 1.",[27,394,29,395,396],"NSCLC (Advanced Non-small Cell Lung Cancer)","Endometrial Cancer","Malignant Melanoma",[398,399],"Ataxia Telangiectasia and Rad3-related protein inhibitor","Advanced solid tumor","2026-01-19",{"date":402,"type":54},"2026-01-28",{"date":404,"type":54},"2025-12-03",{"date":406,"type":20},"2029-06-30",{"name":408,"class":88},"Beijing Tide Pharmaceutical Co., Ltd",{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":73,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":62},"100618654","phase-1-fruquintinib-combined-with-trastuzumab-and-xelox-as-first-line-treatment-in-patients-with-her2-positive-advanced-gastric-cancer-100618654","NCT07334431","Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer","Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: an Open-label, Single-arm, Single-center Phase Ib\u002FII Clinical Study","Inclusion Criteria:\n\n* Have fully understood the study and voluntarily signed the informed consent;\n* 18-75 years old (including 18 and 75 years old);\n* Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma;\n* No previous anti-tumor treatment for metastatic diseases;\n* HER2 positive;\n* Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;\n* Life expectancy ≥ 3 months;\n* At least one measurable lesion according to RECIST version 1.1;\n* The functions of vital organs met the following requirements (Blood components and cell growth factors were not allowed within 14 days before enrollment):\n\n  * Absolute neutrophil count ≥1.5×109\u002FL;\n  * Platelet ≥100×109 \u002FL;\n  * Hemoglobin ≥90g\u002FL;\n  * Total bilirubin \\\u003C 1.5 ULN;\n  * ALT and\u002For AST \\\u003C 1.5 ULN ;\n  * Serum creatinine (Cr) \\\u003C1.5×ULN;\n  * Endogenous creatinine clearance ≥50ml\u002Fmin;\n* Female patients of childbearing age should take effective contraceptive measures;\n* Good compliance, cooperate with follow-up.\n\nExclusion Criteria:\n\n* Failure to comply with the study protocol or study procedure;\n* Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, chemotherapy or immune checkpoint inhibitors;\n* Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;\n* Known presence of symptomatic central nervous system metastasis or brain metastases;\n* Had autoimmune disease or history of autoimmune disease within 4 weeks before enrollment;\n* Previously received allogeneic bone marrow transplantation or organ transplantation;\n* Uncontrolled malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture as determined by the researcher);\n* Severe cardiovascular disease, including unstable angina pectoris or myocardial infarction, occurs within 6 months before the start of study treatment;\n* Subjects who are allergic to the investigational drug or any of its adjuncts;\n* Participated in other domestic unapproved or unmarketed drug clinical trials and accepted the corresponding experimental drug treatment within 4 weeks before enrollment;\n* International Standardized Ratio (INR) \\>1.5 or partially activated prothrombin time (APTT) \\>1.5×ULN;\n* The investigator identified clinically significant electrolyte abnormalities;\n* Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg;\n* Poorly controlled diabetes mellitus was present before enrollment (fasting glucose concentration ≥CTCAE level 2 after formal treatment);\n* Had any disease or condition prior to enrollment that affected drug absorption, or the patient could not take fruquintinib orally;\n* Gastrointestinal diseases such as active ulcer of stomach and duodenum, ulcerative colitis, or active bleeding of unresectosed tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by researchers before enrollment;\n* Patients with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding within 3 months \\>30 mL, hematemesis, stool, stool blood), hemoptysis (within 4 weeks \\>5 mL of fresh blood) or had a thromboembolic event (including stroke events and\u002For transient ischemic attacks) within 12 months;\n* Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe\u002Funstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure \\>Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) \\\u003C50%;\n* Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe\u002Funstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure \\>Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) \\>50%;\n* Unmitigated toxicity higher than CTCAE v5.0 grade 1 due to any previous anticancer therapy, excluding alopecia, lymphocytopenia, and oxaliplatin grade ≤2 neurotoxicity;\n* Women who are pregnant (positive pregnancy test before medication) or breastfeeding;\n* Received blood transfusion therapy, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF), within 14 days before enrollment;\n* Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, which, in the investigator's judgment, reasonably suspects that the patient has a medical condition or condition that is not suitable for the use of the investigational drug (such as having seizures and requiring treatment), or which would affect the interpretation of the study results or place the patient at high risk；\n* Urine routine indicated urinary protein ≥2+, and 24-hour urinary protein volume \\> 1.0g;\n* Complications require long-term treatment with immunosuppressants or systemic or local use of immunosuppressive corticosteroids (\\> 10mg\u002F day prednisone or other therapeutic hormone);\n* Investigators believe that the patient has any other conditions that are not suitable for participating in the study.","75 Years",{"count":418,"type":20},45,[75,100],"This study was designed to evaluate the safety and efficacy of fruquintinib plus trastuzumab, and XELOX as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.",[104,29,422,423,424,425],"GEJ Adenocarcinoma","HER2-positive Gastric Cancer","First-line Therapy","Fruquintinib","2025-12-30",{"date":428,"type":54},"2026-01-12",{"date":430,"type":54},"2024-02-22",{"date":432,"type":20},"2026-12-31",{"name":434,"class":435},"Henan Cancer Hospital","OTHER_GOV",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":62},"100136578","clinical--pathological-studies-of-upper-gastrointestinal-carcinoma-100136578","NCT01048281","Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma","Inclusion Criteria:\n\n1. Over 18\n2. Diagnosed with gastric or esophageal cancer OR at an increased hereditary risk for upper GI cancer\n\nExclusion Criteria:\n\n1. Under 18\n2. No family or personal history of gastric or esophageal cancer",{"count":443,"type":20},100,"Our research of the biology of upper gastrointestinal cancers involves the study of tissue samples and cells from biopsies of persons with gastric or esophageal cancer or blood samples from upper gastrointestinal cancer patients and persons at high inherited risk for these cancers. We hope to learn the role genes and proteins play in the development of gastric and esophageal cancer.",[299,446,29,143,447],"Gastro-Esophageal(GE) Junction Cancer","Gastrointestinal Stromal Tumor (GIST)","2025-12-17",{"date":450,"type":54},"2025-12-18",{"date":452,"type":4},"2002-08",{"date":454,"type":20},"2099-01",{"name":456,"class":61},"Stanford University",{"id":458,"slug":459,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":464,"enrollmentInfo":465,"targetDuration":4,"studyType":73,"phases":467,"briefSummary":468,"conditions":469,"keywords":472,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":481,"leadSponsor":483,"locationsCount":62},"100609311","phase-2-the-safety-and-clinical-efficacy-of-rak-cell-therapy-in-late-stage-gastric-cancer-a-randomized-controlled-trial-100609311","NCT07212933","The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial","RAK in GC","Inclusion Criteria:\n\n* 1\\. Subjects voluntarily join this study and sign the informed consent form. 2. Age ≥18 years and ≤70 years. 3. Confirmed by gastroscopic pathology or imaging (enhanced CT\u002FPET-CT) as Stage IV gastric cancer or gastroesophageal junction adenocarcinoma (cTanyNanyM1). Metastatic sites include but are not limited to: liver, peritoneum, lungs, pancreas, greater omentum, retroperitoneal lymph nodes, etc.\n\n  4\\. Failure or disease progression after prior frontline anti-tumor therapy (including ineffective first- and second-line chemotherapy, targeted therapy, and immunotherapy for advanced gastric cancer).\n\n  5\\. Have measurable solid tumors (efficacy evaluation standard: RECIST 1.1); tumor assessment via CT scan or MRI must be performed within 28 days before treatment.\n\n  6\\. Physical performance status ECOG 0-3. 7. Expected lifespan ≥1 month. 8. Participants must be able to understand the study procedures and agree to participate in the study by providing written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Concurrent other types of malignancy. 2. Severe cardiac, pulmonary, or cerebral system diseases. 3. Expected survival \\\u003C1 month. 4. Laboratory investigations indicating unsuitability for receiving anti-tumor biotherapy:\n\n  1. Moderate to severe bone marrow suppression: (HGB \\\u003C80 g\u002FL; WBC \\\u003C2.0×10⁹\u002FL; ANC \\\u003C1.0×10⁹\u002FL; PLT \\\u003C50×10⁹\u002FL).\n  2. Significantly decreased liver function (Child-Pugh Grade C).\n  3. Severe renal insufficiency (CKD Stage III and above).\n  4. Severe coagulation dysfunction (INR ≥1.5 or APTT \\>1.5 × ULN).","70 Years",{"count":466,"type":20},90,[100],"This project employs a prospective, double-blind, randomized controlled trial methodology to comparatively analyze the safety and survival outcomes of human umbilical cord blood RAK cells applied in advanced gastric cancer. Firstly, the maximum tolerated dose (MTD) of RAK cell therapy for patients with advanced gastric cancer will be determined through a dose-escalation trial. Subsequently, the overall survival (OS), progression-free survival (PFS), and incidence of adverse events will be compared between the RAK treatment group and the control group. This aims to explore the efficacy and safety of biotherapy for recurrent or metastatic gastric cancer where frontline therapy has failed, thereby laying the foundation and providing evidence for large-scale, multi-center clinical studies.",[29,470,471],"Biological Therapy","Immunotherapy",[473,474,475,45,476],"Gastric cancer","late-stage","progression-free survival","T cell biological therapy","2025-10-02",{"date":479,"type":54},"2025-10-08",{"date":237,"type":54},{"date":482,"type":20},"2028-06-30",{"name":484,"class":61},"Chinese PLA General Hospital",{"id":486,"slug":487,"hasResults":11,"nctId":488,"briefTitle":489,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":73,"phases":494,"briefSummary":495,"conditions":496,"keywords":498,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":507,"leadSponsor":509,"locationsCount":156},"100572406","phase-1-a-phase-ibii-trial-of-neoadjuvant-zolbetuximab-plus-docetaxel-oxaliplatin-and-s-1-chemotherapy-in-patients-with-locally-advanced-gastric-cancer-100572406","NCT06732856","A Phase Ib\u002FII Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer","NEO-CLAUD","Inclusion Criteria:\n\n1. Patients with newly diagnosed, pathologically confirmed, potentially resectable gastric or gastroesophageal junction adenocarcinoma\n2. Subjects who are CLDN18.2 positive (VENTANA 43-14A ≥75%)\n3. Patients with clinical stage T3-4\u002FN0 or T2-4\u002FN+ on CT according to the American Joint Committee on Cancer (AJCC) 8th edition\n4. If suspected by CT, patient who has not been confirmed to have peritoneal seeding by laparoscopy\n5. Subject able to provide signed informed consent form, including compliance with the requirements and contraindications specified in the informed consent form (ICF) and in this protocol\n6. Patients aged 19 years or older at study entry\n7. Patient with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n8. Patient with expected survival \\>12 months\n9. Weight \\>30 kg\n10. Patient without neuropathy A. Grade 1 is allowed based on NCI CTCAE v5.0. B. Grade 2 or higher is excluded based on NCI CTCAE v5.0\n11. Individual with confirmed adequate normal organ and bone marrow function, as defined in the applicable items below:\n\n    * Hemoglobin ≥9.0 g\u002FdL\n    * Absolute neutrophil count (ANC) \\>1.5 x 103\u002FmcL (\\>1,500 per mm3)\n    * Platelet count ≥100 x 109\u002FL\n    * Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN)\n    * AST (SGOT)\u002FALT (SGPT) ≤2.5 x institutional ULN\n    * Measured creatinine clearance (CL) \\>40 mL\u002Fmin or creatinine CL \\>40 mL\u002Fmin as calculated by Cockcroft-Gault formula (Cockcroft and Gault 1976) or based on a 24-hour urine sample for determination of creatinine clearance\n\n      1. Male creatinine CL (mL\u002Fmin) = Weight (kg) x (140 - Age) \u002F 72 x Serum creatinine (mg\u002FdL)\n      2. Female creatinine CL (mL\u002Fmin) = Weight (kg) x (140 - Age) \u002F 72 x Serum creatinine (mg\u002FdL) x 0.85\n12. Evidence of menopause, or negative urine\u002Fblood pregnancy test in premenopausal women; women with amenorrhea for at least 12 months without any other medical cause are considered menopausal. The following age requirements apply:\n\n    * A woman under age 50 is considered menopausal if 1) she has had amenorrhea for at least 12 months without hormone therapy, and 2) her LH and FSH blood levels are at menopausal levels or she has undergone bilateral oophorectomy, hysterectomy, etc.\n    * A woman aged 50 years or older is considered menopausal if\n\n      1. she has had amenorrhea for at least 12 months without hormone therapy, or\n      2. she became menopause after 1 year of amenorrhea following radiation or anticancer treatment, or\n      3. she has undergone bilateral oophorectomy, bilateral salpingectomy, hysterectomy, etc.\n13. Patient who is willing and able to comply with the protocol during the study, including treatments and tests such as scheduled visits, follow-up, etc.\n\nExclusion Criteria:\n\n1. Patient who received investigational product in another clinical study 2 weeks prior to participation in this clinical study\n2. Patient currently enrolled in another clinical study, other than the observational (non-interventional) study or follow-up period of an interventional clinical study.\n3. Concomitant chemotherapy, immunotherapy, biologic or hormonal therapy. Hormonal therapies not related to treatment for cancer (e.g., hormone replacement therapy) are allowed.\n4. Major surgical procedure within 28 days prior to zolbetuximab administration\n5. Distant metastasis including M1 lymph node\n6. Patient unable to take oral medication\n7. Gastric outlet obstruction and\u002For severe gastrointestinal hemorrhage that restricts diet without treatment\n8. Impaired intestinal absorption, including:\n\n   * Intestinal obstruction\n   * Chronic inflammatory bowel disease\n   * Operation history of extended bowel resection\n   * Gastric dumping syndrome\n9. Patient with a history of organ transplant\n10. Uncontrolled intercurrent disease including, but not limited to:\n\n    Ongoing or active infection, congestive heart failure with symptoms, uncontrolled hypertension, unstable angina, arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions accompanied with diarrhea, mental illness or social conditions that prevent compliance with study requirements, significantly increase the risk of adverse reactions, or interfere with written consent\n11. History of other primary malignancy, with the exception of:\n\n    * Patient who is at low risk of recurrence with disease-free status for at least 5 years prior to starting chemotherapy due to curative treatment\n    * Patient who is currently disease-free with cured skin cancer (except melanoma) or lentigo maligna\n    * Patient who is currently disease-free with cured in situ carcinoma\n12. Patient with a history of active congenital immunodeficiency\n13. Active infection, such as tuberculosis, confirmed by history, physical examination, radiographic findings, and TB testing per local standards, or HIV.\n\n    * Tuberculosis: History, physical examination, or radiological findings suggestive of active tuberculosis, or tuberculosis confirmed by tuberculosis testing per local standards (active TB is excluded and old TB is allowed)\n    * For HBV infection, the patient may be enrolled if appropriately treated with antiviral agents, etc.\n    * HIV\n\n      1. HIV Ag\u002FAb: If reactive, exclude\n      2. HIV Ag\u002FAb: If non-reactive, enroll\n14. Pregnant or lactating woman and man or woman of childbearing potential who is unwilling to use effective contraception (from the screening period to 90 days after the last dose of zolbetuximab)\n15. Individual with known allergy and hypersensitivity to the investigational product or its components",{"count":493,"type":20},57,[75,100],"Claudin 18.2 is a promising therapeutic target overexpressed on the surface of gastric cancer cells. The addition of zolbetuximab, the monoclonal antibody targeting Claudin 18.2 to chemotherapy in two recent Phase 3 studies prolonged survival outcomes, indicating that Claudin 18.2 is a valid target in gastric cancer. Asan Medical Center researchers conducted a study on Claudin 18.2 expression in patients with operable gastric cancer and defined moderate to strong claudin expression in more than 75% of tumor cells as Claudin 18.2 overexpression, which was observed in 46.5% of patients with stage I-III tumors. This suggests that zolbetuximab-based treatment may be possible in patients with LAGC.\n\nTherefore, The investigator designed a prospective, multicenter, open-label, Phase Ib\u002FII study to determine the efficacy and safety of zolbetuximab\u002FDOS as neoadjuvant chemotherapy in patients with LAGC.",[497,29],"Stomach Neoplasm",[499,500,501,502],"NEO-ADJUVANT","ADJUVANT","distant metastasis limited to lymph node gastric cancer","unresectable locally advanced gastric cancer","2025-07-24",{"date":505,"type":54},"2025-07-28",{"date":56,"type":54},{"date":508,"type":20},"2027-12-31",{"name":510,"class":61},"Asan Medical Center",{"id":512,"slug":513,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":228,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":4},"100588620","fecal-dna-methylation-and-helicobacter-pylori-gastric-cancer-susceptibility-genes-test-100588620","NCT06943768","Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test","Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes for the Early Diagnosis and Screening of Gastric Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years old, male or female not limited.\n* Within 90 days, the gastroscopy and\u002For pathological results confirm the absence of gastric cancer.\n* Patients must be able to fully understand the informed consent form and be able to personally sign it.\n\nExclusion Criteria:\n\n* Severe cardiac, hepatic, or renal insufficiency, or psychiatric disorders.\n* A previous history of malignant tumors of the upper gastrointestinal tract.\n* Women during pregnancy.\n* Those with undefined pathology.\n* Those with unsatisfactory sample retention (e.g., too small a sample size)",{"count":519,"type":20},9654,"This is a multicenter, cross-sectional study. It is based on fecal methylation site detection, H. pylori susceptibility testing of fecal samples, and a combination of the two, compared with the \"gold standard\" imaging tests, CT, gastroscopy and\u002For pathology, for gastric cancer, benign diseases such as gastritis, and health check-ups.",[29],"2025-06-21",{"date":524,"type":54},"2025-06-24",{"date":526,"type":20},"2025-12-01",{"date":53,"type":20},{"name":241,"class":61},{"id":530,"slug":531,"hasResults":11,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":416,"enrollmentInfo":535,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":156},"100591397","investigating-multigene-methylation-dynamics-in-treatment-response-surveillance-for-gastric-cancer-100591397","NCT06979895","Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer","Inclusion Criteria:\n\nAge at initial diagnosis: 18-75 years Histologically confirmed gastric or gastroesophageal junction malignancy, with complete medical records, confirmed pathological diagnosis, and definitive staging data (TNM staging system) No history of other primary malignancies Absence of distant metastases (liver, lung, or other sites) confirmed by imaging examination (CT\u002FMRI) No prior surgical resection, chemotherapy, or PD-1\u002FPD-L1 immunotherapy before enrollment Availability of complete biospecimen information, including: Sample ID (medical record number), Demographic data (sex, age), Clinical diagnostic data, Tumor marker profiles (CEA, CA19-9, etc.)\n\nExclusion Criteria:\n\nLife expectancy \\\u003C6 months (as assessed by ECOG score ≥4 or Palliative Performance Scale ≤30%) Cognitive\u002Fpsychiatric conditions: a. Legally incapacitated individuals without legal guardians, b. Active psychotic disorders (e.g., schizophrenia, bipolar disorder) or dementia (MMSE score \\\u003C24) Investigator-determined exclusions",{"count":536,"type":20},150,"The primary objective is to determine whether pretreatment-to-posttreatment changes in circulating multigene methylation levels correlate with objective response rates (ORR) assessed by contrast-enhanced CT\u002FMRI and levels of serum tumor markers. Secondary endpoints include: (a) time-dependent association between methylation fluctuation patterns and progression-free survival (PFS), (b) comparative diagnostic accuracy of methylation indices versus conventional biomarkers, and (c) feasibility of using methylation thresholds to guide adaptive therapy modification.",[29],"2025-05-18",{"date":541,"type":54},"2025-05-20",{"date":543,"type":20},"2025-05-25",{"date":545,"type":20},"2030-03-01",{"name":547,"class":61},"Xijing Hospital",{"id":549,"slug":550,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":416,"enrollmentInfo":555,"targetDuration":4,"studyType":73,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":565,"locationsCount":156},"100573140","phase-1-xelox-combined-with-sintilimab-and-hbo-for-advanced-or-metastatic-gcgejc-100573140","NCT06742411","XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC\u002FGEJC","A Phase Ib\u002FII Clinical Trial of the XELOX Regimen Combined With Sintilimab and Hyperbaric Oxygen Therapy for the Treatment of Advanced or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma","Inclusion criteria:\n\n1.Diagnosis: Histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (including signet ring cell carcinoma, mucinous adenocarcinoma, and hepatoid adenocarcinoma).\n\n2.Disease status: The presence of metastatic disease, attributable to either recurrence or distant dissemination, was established through a combination of radiologic or surgical assessments.\n\n3.Survival Expectancy: Predicted to live more than 3 months. 4.Age: 18-75 years. 5.Prior treatments:\n\n1. There are no previous antitumor treatments (chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy, etc.).\n2. If patients previously received adjuvant or neoadjuvant therapy, the last treatment must have been completed at least 6 months before randomization, with no recurrence or disease progression during treatment.\n3. Palliative radiotherapy is allowed if it is completed at least 2 weeks before the first study treatment.\n4. The use of prior anti-tumor traditional Chinese medicine is allowed if it is discontinued at least 2 weeks before randomization.\n\n6.Performance Status: ECOG PS ≤1. 7.Assessable lesion: At least one measurable lesion per the RECIST 1.1 criteria.\n\n8.Pathological samples: Patients whose archived or fresh pathological tissue was obtained within 6 months before signing informed consent, which was sufficient for PD-L1 testing with obtainable results, were included.\n\n9.Organ function:\n\n1. Hematology (no transfusion or G-CSF use within 14 days before screening):\n\n   Hemoglobin ≥90 g\u002FL. Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL. Platelet count ≥75×10⁹\u002FL.\n2. Biochemistry (no albumin use within 14 days before screening):\n\nAlbumin ≥28 g\u002FL. Total bilirubin ≤1.5×ULN. AST and ALT levels were ≤3×ULN (≤5×ULN if liver metastasis was present). creatinine ≤1.5×ULN. (3)Coagulation: INR or PT ≤1.5×ULN. APTT ≤1.5×ULN. 10.Systemic treatment history: No systemic treatment (including adjuvant\u002Fneoadjuvant) was given within the past 6 months after sample collection for randomization.\n\n11.Toxicity: Prior antitumor treatment or surgery-related acute toxic reactions were resolved to grade 0-1 per NCI CTCAE v5.0 or to levels specified by the inclusion\u002Fexclusion criteria.\n\n12.Contraception: Strict contraception measures. 13.Consent and Compliance: Signed informed consent, willing and able to comply with study visits, treatments, lab tests, and procedures.\n\nExclusion criteria:\n\n1. HER2 status: HER2-positive (HER2 3+ or 2+ \\& FISH+).\n2. Tumor type: Nonadenocarcinoma gastric cancers, including squamous cell carcinoma, undifferentiated carcinoma, or mixed histological types.\n3. CNS Metastasis: Uncontrolled or symptomatic active CNS metastasis (e.g., clinical symptoms, brain edema, spinal cord compression, carcinomatous meningitis, soft meningeal disease, or progressive growth).\n4. Fluid accumulation: Uncontrolled pleural effusion or ascites treated with drainage within 14 days before randomization; symptomatic or moderate to large pericardial effusion.\n5. Weight loss: Weight loss \\>20% within 2 months before randomization.\n6. Recent treatments:\n\n(1)Major surgery within 28 days before randomization (diagnostic biopsies and PICC placement allowed).\n\n(2)Immunosuppressive drugs should be used within 7 days before randomization, excluding nasal\u002Finhaled corticosteroids or physiological-dose systemic steroids (≤10 mg\u002Fday prednisone or equivalent).\n\n(3)Live attenuated vaccines were administered within 28 days before randomization, during the study, or within 60 days after treatment ended.\n\n(4)Antitumor treatments were administered within 28 days before randomization (chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy, or tumor embolization).\n\n7.Other Malignancies: Patients were diagnosed with any other malignancy within 3 years before study entry, except for localized and cured basal cell carcinoma, squamous or superficial bladder carcinoma, cervical carcinoma in situ, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma.\n\n8.Autoimmune Diseases: Any active, known, or suspected autoimmune disease. Stable conditions not requiring systemic immunosuppression are allowed (e.g., type I diabetes; hypothyroid diabetes managed with hormone replacement; and skin diseases not needing systemic treatment, such as vitiligo, psoriasis, and alopecia).\n\n9.Neurological\u002FPsychiatric Conditions: Uncontrolled epilepsy, congenital spherocytosis, claustrophobia, or angle-closure glaucoma.\n\n10.Immune therapy history: Prior treatment with anti-PD-1\u002FPD-L1 antibodies, anti-CTLA-4 antibodies, or other T-cell costimulation\u002Fcheckpoint pathway drugs.\n\n11.Bleeding\u002Fthrombosis events: significant bleeding symptoms or tendencies within 3 months before randomization; gastrointestinal perforation or fistula within 6 months; thrombotic events (e.g., stroke, deep vein thrombosis, pulmonary embolism) within 6 months.\n\n12.Major Vascular Disease: Major vascular disease within 6 months before study treatment (e.g., aortic aneurysm needing surgery or recent peripheral arterial thrombosis).\n\n13.Wounds and fractures: Severe, unhealed, or open wounds; active ulcers; or untreated fractures.\n\n14.Neuropathy: Peripheral neuropathy \\>Grade 1. 15.Intestinal Obstruction: History of intestinal obstruction or related symptoms within 6 months before study treatment. Patients treated surgically to resolve incomplete obstructions at initial diagnosis may be included.\n\n16.Systemic diseases: Interstitial lung disease, noninfectious inflammation, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, acute pneumonia).\n\n17.Drug Allergies: Patients with known severe allergic reactions to the study drugs or any monoclonal antibodies.\n\n18.HIV\u002FAIDS: HIV infection or known AIDS. 19.Hepatitis: Untreated active hepatitis B (HBV-DNA ≥500 IU\u002Fml), hepatitis C (HCV-RNA above the detection limit), or coinfection with HBV and HCV.\n\n20.Cardiac conditions: Myocardial infarction, severe\u002Funstable angina, NYHA Class II or higher heart failure, significant arrhythmias, or congestive heart failure within 6 months before randomization.\n\n21.Hypertension: Poorly controlled hypertension despite treatment (systolic BP \\>140 mmHg or diastolic BP \\>90 mmHg).\n\n22.Infections and Fever: Systemic antibiotic use ≥7 days within 4 weeks before randomization or unexplained fever \\>38.5°C during screening\u002Fbefore the first dose (tumor-related fever allowed on the basis of the investigator's judgment).\n\n23.Transplant history: Known history of allogeneic organ or hematopoietic stem cell transplantation.\n\n24.Other Clinical Trials: Participation in any other drug clinical trial within 4 weeks before randomization or within 5 half-lives of the last study drug.\n\n25.Substance Abuse: History of psychiatric drug abuse or drug addiction. 26.Other Severe Conditions: Any other serious physical or mental illness, abnormal lab tests increasing study risk or interfering with results, or deemed unsuitable by the investigator.\n\n27.The pulmonary conditions were as follows: treated pneumothorax, severe emphysema, or pulmonary bullae.",{"count":493,"type":20},[75,100],"This study investigates the efficacy and safety of XELOX chemotherapy combined with sintilimab and hyperbaric oxygen therapy (HBOT) as a first-line treatment for patients with Advanced or Metastatic gastric and gastroesophageal junction adenocarcinoma. The trial comprises two phases: a phase Ib study to determine the optimal HBOT regimen and assess safety and tolerability, followed by a phase II study to evaluate the overall response rate (ORR). Secondary outcomes include progression-free survival (PFS), disease control rate (DCR), 2-year disease-free survival (DFS), 2-year overall survival (OS), safety, and quality of life. This study aims to provide a novel approach for enhancing therapeutic efficacy and improving patient outcomes by leveraging HBOT to address tumor hypoxia and augment the effects of chemotherapy and immune checkpoint inhibitors.",[29],"2025-05-03",{"date":561,"type":54},"2025-05-07",{"date":563,"type":54},"2024-12-31",{"date":432,"type":20},{"name":566,"class":61},"West China Hospital",{"id":568,"slug":569,"hasResults":11,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":416,"enrollmentInfo":574,"targetDuration":4,"studyType":73,"phases":576,"briefSummary":577,"conditions":578,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":587,"locationsCount":62},"100583069","phase-1-fruquintinib-combined-with-pd-1-inhibitor-and-folfox-as-first-line-treatment-for-advanced-gastric-cancer-100583069","NCT06871527","Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer","Fruquintinib Combined With Tislelizumab and FOLFOX as First-Line Treatment For Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-center, Open-label, Phase Ib\u002FII Clinical Study","Inclusion Criteria:\n\n* 18-75 years old (including 18 and 75 years old);\n* Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;\n* Pathologically determined gastric or gastroesophageal junction adenocarcinoma;\n* Advanced patients with radiographic confirmation of inoperable complete resection;\n* No previous anti-tumor treatment for metastatic diseases;\n* At least one measurable lesion according to RECIST version 1.1;\n* Ability to take medications orally;\n* No active bleeding;\n* Adequate organ functions:\n\nAbsolute neutrophil count ≥2×109\u002FL; Platelet ≥100×109\u002FL; Hemoglobin ≥90g\u002FL; WBC≥4×109\u002FL Total bilirubin ≤ 1.5XULN; ALT and AST ≤2.5XULN ； Serum creatinine (Cr) ≤1.5XULN；\n\n• Have fully understood the study and voluntarily signed the informed consent;\n\nExclusion Criteria:\n\n* Patients who had received any drug in the study protocol in the last year;\n* Deficient mismatch repair (dMMR) or MSI-H detected by genetic test;\n* HER2 positive（HER-2 3+, or HER-2 2+ and FISH+）;\n* Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥90 mmHg;\n* Patients with acute coronary syndromes (including myocardial infarction and unstable angina) received coronary angioplasty or stenting within 6 months before enrollment;\n* Patients with massive pleural or peritoneal effusion requiring drainage;\n* Patients with severe ECG abnormalities or heart diseases (such as cardiac insufficiency, myocardial infarction, angina pectoris) that affect clinical treatment;\n* Severe lung diseases (such as interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc.);\n* Mental disorders or central nervous system diseases or brain metastases affecting clinical treatment;\n* Patients with autoimmune diseases;\n* Patients with grade 3 or higher bleeding within 4 weeks;\n* Patients with a history of allergy to any drug, similar drug or vehicle in this study;\n* Had a major surgical procedure (thoracotomy, or laparotomy , etc.) within 4 weeks prior to the first dose of study therapy;\n* Patients with nonhealed wounds, ulcers, or fractures;\n* Patients who required systemic corticosteroids (excluding temporary testing, prophylactic administration for anaphylaxis), or immunosuppressive agents or had received such agents within 14 days before enrollment;\n* Pregnant or lactating women, or patients of childbearing age who refused contraception during the study period;\n* Investigators believe that the patient has any other conditions that are not suitable for participating in the study.",{"count":575,"type":20},44,[75,100],"This study was designed to explore the efficacy and safety of fruquintinib combined with tislelizumab and FOLFOX regimen as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.",[29,104,425,579,580,422],"PD-1 Inhibitor","Tislelizumab","2025-03-11",{"date":583,"type":54},"2025-03-12",{"date":585,"type":20},"2025-03-01",{"date":218,"type":20},{"name":588,"class":61},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":590,"slug":591,"hasResults":11,"nctId":592,"briefTitle":593,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":416,"enrollmentInfo":596,"targetDuration":598,"studyType":21,"phases":4,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":605,"leadSponsor":607,"locationsCount":4},"100582079","development-of-a-predictive-model-for-gastric-cancer-peritoneal-metastasis-and-cachexia-using-bub1-and-radiopathomics-data-with-deep-learning-100582079","NCT06858644","Development of a Predictive Model for Gastric Cancer Peritoneal Metastasis and Cachexia Using BUB1 and Radiopathomics Data With Deep Learning","BUDDLE","Inclusion Criteria:\n\nAdults aged 18-75 years diagnosed with gastric cancer (GC) at any stage. Histopathologically confirmed GC with available radiological (CT\u002FMRI) and pathological data (biopsy samples).\n\nPatients with or at risk of peritoneal metastasis and\u002For cachexia, as determined by clinical assessment and imaging.\n\nAbility to provide informed consent and comply with study protocols. Willingness to undergo regular follow-up imaging and clinical evaluation for the duration of the study.\n\nExclusion Criteria:\n\nPatients with other primary cancers or serious comorbidities (e.g., severe cardiovascular disease, uncontrolled diabetes).\n\nPregnant or breastfeeding women. Patients with contraindications to MRI or CT imaging. Those with insufficient clinical data (e.g., missing radiopathological information) for model training.\n\nPatients who are unable or unwilling to comply with the study protocol, including follow-up visits and evaluations.",{"count":597,"type":20},500,"5 Years","This clinical trial aims to develop a predictive model for gastric cancer (GC) peritoneal metastasis and cachexia by integrating BUB1 gene data with radiological and pathological data using advanced deep learning techniques. The study will focus on utilizing imaging genomics (radiomics) and histopathological data to identify early biomarkers for peritoneal metastasis and cachexia in GC patients. By leveraging deep learning algorithms, the project seeks to improve the accuracy and reliability of predictions, enabling earlier intervention and personalized treatment strategies. The ultimate goal is to enhance clinical decision-making and prognosis prediction in GC patients with peritoneal metastasis and cachexia.",[29],"2025-02-27",{"date":603,"type":54},"2025-03-05",{"date":585,"type":20},{"date":606,"type":20},"2027-03-01",{"name":608,"class":61},"Qun Zhao",{"id":610,"slug":611,"hasResults":11,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":617,"targetDuration":4,"studyType":73,"phases":619,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":156},"100573609","phase-2-comparing-the-efficacy-of-sintilimab-plus-nab-pof-regimen-sintilimab-plus-xelox-chemotherapy-and-lenvatinib-sintilimab-plus-xelox-chemotherapy-in-the-treatment-of-her2-negative-metastatic-gastric-cancer-100573609","NCT06748508","Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer","A Multicenter, Prospective, Open-label, Randomized Controlled, Phase II Clinical Trial Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer","FDZL-GC003","Inclusion Criteria:\n\n1. Males or females aged over than 18 years\n2. Histologically or cytologically confirmed gastric adenocarcinoma (including GEJ adenocarcinoma)\n3. Presence of measurable lesions(RECIST 1.1)\n4. Newly diagnosed patients; or patients with recurrence after surgery, who have been off adjuvant chemotherapy for at least 6 months and have not received any anti-cancer treatment within the past 6 months\n5. ECOG PS score: 0-1\n6. Expected survival over than 3 months\n7. Normal major organ function or reserve, meeting the following criteria (determined by laboratory test data within 7 days (inclusive) before screening): HB ≥90 g\u002FdL, ANC ≥1.5×109\u002FL, PLT ≥100×109\u002FL; BIL\\\u003C1.5×ULN, ALT and AST \\\u003C2.5×ULN, if with metastases to liver, then ALT, AST \\\u003C5×ULN; serum Cr≤1×ULN, endogenous creatinine clearance \\>50 mL\u002Fmin (calculated by CK formula), international normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN, if the subject is receiving anticoagulant therapy, PT should be within the intended range of the anticoagulant drug\n8. Subjects who voluntarily participate in this study, sign the informed consent form, have good compliance, and cooperate with follow-up\n\nExclusion Criteria:\n\n1. Histopathological assessment of HER2 positivity (immunohistochemistry 3+ or immunohistochemistry 2+ and FISH positive)\n2. Known dMMR\u002FMSI-H\n3. History of other malignant neoplasms within 3 years prior to enrollment, except for cured cervical carcinoma in situ or basal cell carcinoma\n4. Presence of brain metastases to meninges\n5. Malignant pleural or peritoneal effusion\n6. Presence of gastrointestinal obstruction, gastrointestinal haemorrhage (fecaloccult blood +++ or higher), or perforation\n7. Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2, CD137, CTLA-4 antibodies, or any other antibody or drug specifically targeting T-cell co-stimulatory or checkpoint pathways\n8. Subjects with active or history of autoimmune diseases that might relapse (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disorder, multiple sclerosis, vasculitis, glomerulonephritis, etc.), or high-risk patients (e.g., those requiring immunosuppression after organ transplant), except for those with vitiligo, psoriasis, alopecia, or Graves' disease that have not required systemic treatment within the past 2 years, or hypothyroidism requiring only thyroid hormone replacement therapy, or Type I diabetes mellitus requiring only insulin replacement therapy\n9. Current interstitial lung disorder or pneumonia, pulmonary fibrosis, acute lung disorder, or radiation pneumonitis\n10. Participation in other drug clinical studies within 4 weeks prior to the first dose (based on the use of investigational drug), except observational (non-interventional) clinical studies\n11. Use of immunosuppressant drugs within 4 weeks prior to the first dose of study treatment, excluding nasal, inhaled, or other topical glucocorticoids or physiological doses of systemic glucocorticoids (i.e., no more than 10 mg\u002Fday of prednisone or equivalent dose of other glucocorticoids), or short-term (no more than 7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases\n12. Receipt of live attenuated vaccines within 4 weeks prior to the first dose of study treatment or planned immunization during the study period. Note: Inactivated seasonal influenza vaccines for injection are allowed within 4 weeks prior to the first dose; however, live attenuated influenza vaccines are not allowed.\n13. Major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose of study treatment or anticipated need for major surgery (not related to this study) during the study treatment period.\n14. History of human immunodeficiency virus (HIV) infection (i.e., HIV antibody positive), or other acquired or congenital immunodeficiency diseases, or history of organ transplant or stem cell transplant\n15. Active chronic hepatitis B or active hepatitis C; hepatitis B virus carriers, but patients with stable hepatitis B viral loads after drug therapy (HBV DNA ≤ 200 IU\u002FmL or copy number \\\u003C 1000 copies\u002FmL), and patients who have cleared hepatitis C virus (HCV RNA negative) are eligible for enrollment\n16. Known active pulmonary tuberculosis\n17. Patients with severe infection within 4 weeks before the first dose, or active infection requiring oral or vein antibiotic therapy within 2 weeks before the first dose\n18. Symptomatic congestive cardiac failure (New York Heart Association Class II-IV) or symptomatic or poorly controlled arrhythmia\n19. Uncontrolled hypertension (blood pressure systolic ≥160 mmHg or blood pressure diastolic ≥100 mmHg) despite standard treatment\n20. Any arterial embolism event within 6 months before enrollment, including myocardial infarction, angina unstable, cerebrovascular accident, or transient ischemic attack\n21. History of deep vein thrombosis, pulmonary embolism, or any other severe embolism within 3 months before enrollment (thrombosis originating from implanted venous access port or catheter, or superficial vein thrombosis is not considered as \"severe\" thromboembolism)\n22. History of definite neurological or mental disorder: such as epilepsy, dementia, poor compliance, or peripheral nervous system disorders\n23. Alcohol dependence or history of drug addiction or drug abuse within the past year\n24. Pregnant or lactating women,women of childbearing potential who are not taking adequate contraception\n25. Other acute or chronic disease, mental disorder, or laboratory test abnormality that might lead to the following results: increased risk associated with study participation or study drug administration, or interference with the interpretation of study results, and the investigator judges the patient to be ineligible for participation in this study.",{"count":618,"type":20},141,[100],"This trial is a prospective, open, randomized, phase II clinical study. It compares the current first-line treatment for advanced gastric cancer in phase II clinical trials, with the best efficacy being the combination of orient-16 study with sintilimab and XELOX regimen. The purpose of this study is to evaluate whether adding anti-angiogenic drugs or chemotherapy drugs on the basis of two-drug chemotherapy regimen (XELOX regimen) and PD-1 monoclonal antibody can improve efficacy for advanced gastric cancer.",[29],"2024-12-22",{"date":624,"type":54},"2024-12-27",{"date":626,"type":20},"2024-12-25",{"date":628,"type":20},"2027-12-25",{"name":241,"class":61}]